Enanta Pharmaceuticals, Inc. announced the appointment of Matthew P. Kowalsky, J.D., as chief legal officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. Mr. Kowalsky brings more than 20 years of experience handling legal matters across a range of disciplines, including corporate governance, public company reporting, intellectual property, financing, business development and M&A activities in the life sciences industry.

Prior to joining Enanta, Mr. Kowalsky held legal and operational roles of increasing responsibility at Sigilon Therapeutics, Inc., until its acquisition by Eli Lilly in 2023. Most recently, he served as the Chief of Staff and Chief Legal and Administrative Officer of Sigilon, which he joined in 2019 as its General Counsel and Corporate Secretary. Prior to Sigilon, Mr. Kowalsky was Vice President of Legal and Corporate Secretary at Proteon Therapeutics, Inc. from 2016 to 2019.

Previously, he served as Senior Corporate Counsel at Sanofi Genzyme, supporting business development activities, marketed products and alliances for the rare disease business. Earlier, Mr. Kowalsky held similar roles at Cubist Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc. and Lantheus Medical Imaging, Inc., formerly Bristol-Myers Squibb Medical Imaging, Inc.Mr. Kowalsky began his legal career in the corporate and intellectual property groups of Choate, Hall & Stewart LLP. He holds a B.A. from the University of Notre Dame and a J.D. from the Notre Dame Law School.

Before attending law school, he served as a surface warfare officer in the U.S. Navy.